Sign in Sign up for free

Last updated: 28 May 2024 at 4:56pm EST

Roger Stoll Net Worth



Roger Stoll DCTH stock SEC Form 4 insiders trading

Roger has made over 6 trades of the Delcath Systems stock since 2009, according to the Form 4 filled with the SEC. Most recently he bought 4,900 units of DCTH stock worth $8,575 on 28 September 2018.

The largest trade he's ever made was buying 25,000 units of Delcath Systems stock on 18 November 2009 worth over $90,000. On average, Roger trades about 3,236 units every 133 days since 2009. As of 28 September 2018 he still owns at least 5,901 units of Delcath Systems stock.

You can see the complete history of Roger Stoll stock trades at the bottom of the page.





Roger Stoll biography

Dr. Roger G. Stoll Ph.D. serves as Non-Executive Independent Chairman of the Board of the Company. He was appointed as a director of in December 2008. Executive Chairman in September, 2014 and has served as Chairman of the Board since October 1, 2015. From 2002 to 2010 he served as Chairman and Chief Executive Officer of Cortex Pharmaceuticals, Inc. In August of 2010 he was appointed Executive Chairman of the board Cortex and retired in 2012. From 2001 to 2002 he was a consultant to several east coast venture capital firms and startup ventures. From 1998 to 2001, he was Executive Vice President of Fresenius Medical Care-North America, in charge of the dialysis products division and the diagnostic business units, which included hemodialysis machines, dialysis filters, dialysate solutions, and attendant devices used in the dialysis procedure. Dr. Stoll obtained his BS in Pharmacy degree at Ferris State University, his PhD in Biopharmaceutics and drug metabolism at the University of Connecticut and was a post-doctoral fellow for two years at the University of Michigan. He served on the board of Agensys, Inc from 2003 until its sale to Astellas in late 2007. Also on the board of Questcor Pharmaceuticals, and Chelsea Therapeutics until it was acquired in 2008 by Lundbeck A/S. From 1991 to 2002 he also served on the board of directors of St.Jude Medical. He also served on the boards of HIMA and PMA (now PhRMA). Dr. Stoll also serves on the University of Connecticut School of Pharmacy Advisory Board. The nominations committee considered Dr. Stoll's experience and qualifications in both pharmaceuticals and medical devices and equipment in addition to his relevant executive management experience. as well as, the overall composition of the Board, in making the determination that Dr. Stoll should serve as a director of Delcath.

What is the salary of Roger Stoll?

As the Non-Executive Independent Chairman of the Board of Delcath Systems, the total compensation of Roger Stoll at Delcath Systems is $113,666. There are 3 executives at Delcath Systems getting paid more, with John Purpura having the highest compensation of $682,541.



How old is Roger Stoll?

Roger Stoll is 78, he's been the Non-Executive Independent Chairman of the Board of Delcath Systems since 2018. There are no older and 9 younger executives at Delcath Systems.

What's Roger Stoll's mailing address?

Roger's mailing address filed with the SEC is C/O DELCATH SYSTEMS, INC., 566 QUEENSBURY AVENUE, QUEENSBURY, NY, 12804.

Insiders trading at Delcath Systems

Over the last 5 years, insiders at Delcath Systems have traded over $0 worth of Delcath Systems stock and bought 1,192,084 units worth $8,856,388 . The most active insiders traders include Marco Taglietti, Gerard J Michel, and Advisors, Inc. Rosalind. On average, Delcath Systems executives and independent directors trade stock every 25 days with the average trade being worth of $242,307. The most recent stock trade was executed by Gil Aharon on 19 March 2024, trading 26,882 units of DCTH stock currently worth $100,001.



What does Delcath Systems do?

Delcath Systems, Inc., an interventional oncology company, focuses on the treatment of primary and metastatic liver cancers in the United States and Europe. The company's lead product candidate is HEPZATO KIT, a melphalan hydrochloride for injection/hepatic delivery system to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. Its clinical development program for HEPZATO includes the FOCUS clinical trial for patients with hepatic dominant ocular melanoma to investigate objective response rate in metastatic ocular melanoma; and the ALIGN trial, a Phase 3 clinical trial for intrahepatic cholangiocarcinoma. The company also provides HEPZATO as a stand-alone medical device for sale under the CHEMOSAT Hepatic Delivery System for Melphalan trade name for medical centers to treat a range of liver cancers in Europe. Delcath Systems, Inc. was incorporated in 1988 and is headquartered in New York, New York.



What does Delcath Systems's logo look like?

Delcath Systems, Inc. logo

Delcath Systems executives and stock owners

Delcath Systems executives and other stock owners filed with the SEC include: